Becton, Dickinson and Company (BDX) Financials

Becton, Dickinson and Company’s recent results show improving revenue growth, but earnings quality and liquidity remain mixed. Revenue reached $4.98 billion in Q3 2026, up approximately 5.4% from $4.73 billion in Q3 2025 and 5.2% from Q2 2025. However, profitability has been volatile because of restructuring costs, discontinued operations and elevated financing expenses.

• Revenue growth has accelerated. Quarterly revenue increased from $4.59 billion in Q1 2023 to $4.98 billion in Q3 2026. The latest year-over-year gains of roughly 5% are stronger than the low-single-digit growth seen in some earlier periods.
• Gross profit remains substantial. Q3 2026 gross profit was $2.32 billion, producing a gross margin of approximately 46.5%. Although slightly below Q3 2025’s roughly 47.3% margin, the company continues to generate significant cash before operating expenses.
• Continuing operations returned to profitability after a difficult second quarter. Continuing-operations net income improved from a $37 million loss in Q2 2026 to $451 million in Q3 2026. Excluding discontinued operations, Q3 earnings were approximately equal to the prior-year period.
• Debt balances have declined from the prior year. Short- and long-term debt totaled approximately $16.8 billion at the end of Q3 2026, down from $19.3 billion a year earlier. This reduction could lower future interest costs and improve financial flexibility.
• Dividend payments have continued to rise. Cash dividends per share increased from $0.87 in late 2022 to $1.05 in Q1 through Q3 2026. The company also generated $776 million of operating cash flow in Q3, comfortably above its $286 million dividend payment.
• Operating cash flow is positive but uneven. Cash flow from operations was $657 million in Q1 2026, $671 million in Q2 and $776 million in Q3. That is a healthy source of liquidity, but Q3 was well below the $1.22 billion generated in Q3 2025, largely because changes in operating assets and liabilities consumed $339 million.
• Share repurchases have supported per-share results, but activity is inconsistent. BDX repurchased $2.0 billion of common stock in Q2 2026 and $250 million in Q1, while the weighted average share count fell from 285.4 million in Q4 2025 to 272.4 million in Q3 2026. No Q3 repurchase was reported, so investors should determine whether the lower share count is sustainable.
• Operating margins have weakened from earlier levels. Q3 2026 operating income was $663 million, or approximately 13.3% of revenue, compared with $739 million, or 15.6%, in Q3 2025. Selling, general and administrative expense rose to $1.26 billion from $1.16 billion year over year, absorbing much of the benefit from higher revenue.
• Restructuring charges continue to distort earnings. BDX recorded a $533 million restructuring charge in Q2 2026 and another $89 million in Q3. These costs are lower than in Q2 but remain material, making reported earnings less representative of recurring operating performance.
• Liquidity has become tighter. At June 30, 2026, total current assets were $8.14 billion versus $9.40 billion of current liabilities, implying a current ratio below 1.0. The company held $863 million of cash and restricted cash, but accounts payable and short-term debt remained sizable.

Investors should also account for restatements and discontinued operations. Several historical periods in the supplied data were restated, and Q2 2026 included a $274 million loss from discontinued operations while Q3 included a $74 million loss. As a result, consolidated net income does not always reflect the performance of BDX’s ongoing medical technology operations.

Overall, the trend is mixed: revenue growth and debt reduction are constructive, and continuing operations recovered sharply in Q3. However, weaker operating margins, recurring restructuring charges, volatile working-capital cash flow and a current ratio below 1.0 suggest that investors should focus on normalized operating earnings and free cash flow rather than reported net income alone.